Skip to main content
Journal cover image

Polyfunctional cytomegalovirus-specific immunity in lung transplant recipients receiving valganciclovir prophylaxis.

Publication ,  Journal Article
Snyder, LD; Medinas, R; Chan, C; Sparks, S; Davis, WA; Palmer, SM; Weinhold, KJ
Published in: Am J Transplant
March 2011

Cytomegalovirus (CMV) is a common opportunistic infection after lung transplant. Despite effective antiviral medications to treat CMV, invasive CMV disease contributes to lung allograft dysfunction and worse survival. Efforts to prevent CMV have led to the use of valganciclovir prophylaxis for increasingly longer periods after transplant. A pivotal concern with long-term antiviral prophylaxis is that it may prevent or delay the development of CMV-specific immunity and increase the subsequent risk of late onset disease. To address this issue, we conducted a pilot study to determine if CMV-specific immunity was detectable in lung transplant recipients at risk for CMV while on antiviral prophylaxis. Utilizing polychromatic flow cytometry panels, CMV-specific immunity was determined by peripheral blood CD4 and CD8 T cell expression of cytokines in response to the HLA restricted CMV peptides pp65 and IE-1. We determined CMV seropositive lung transplant recipients on valganciclovir for a median of 6 months from transplant have a detectable polyfunctional CMV-specific T cell response which is comparable to seropositive recipients not on antiviral medications and to healthy seropositive nontransplant controls. Thus, valganciclovir prophylaxis does not appear to impair the development of CMV-specific immunity in lung transplantation.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am J Transplant

DOI

EISSN

1600-6143

Publication Date

March 2011

Volume

11

Issue

3

Start / End Page

553 / 560

Location

United States

Related Subject Headings

  • Valganciclovir
  • T-Lymphocytes
  • Surgery
  • Risk Factors
  • Postoperative Complications
  • Pilot Projects
  • Middle Aged
  • Male
  • Lung Transplantation
  • Immunity, Cellular
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Snyder, L. D., Medinas, R., Chan, C., Sparks, S., Davis, W. A., Palmer, S. M., & Weinhold, K. J. (2011). Polyfunctional cytomegalovirus-specific immunity in lung transplant recipients receiving valganciclovir prophylaxis. Am J Transplant, 11(3), 553–560. https://doi.org/10.1111/j.1600-6143.2010.03405.x
Snyder, L. D., R. Medinas, C. Chan, S. Sparks, W. A. Davis, S. M. Palmer, and K. J. Weinhold. “Polyfunctional cytomegalovirus-specific immunity in lung transplant recipients receiving valganciclovir prophylaxis.Am J Transplant 11, no. 3 (March 2011): 553–60. https://doi.org/10.1111/j.1600-6143.2010.03405.x.
Snyder LD, Medinas R, Chan C, Sparks S, Davis WA, Palmer SM, et al. Polyfunctional cytomegalovirus-specific immunity in lung transplant recipients receiving valganciclovir prophylaxis. Am J Transplant. 2011 Mar;11(3):553–60.
Snyder, L. D., et al. “Polyfunctional cytomegalovirus-specific immunity in lung transplant recipients receiving valganciclovir prophylaxis.Am J Transplant, vol. 11, no. 3, Mar. 2011, pp. 553–60. Pubmed, doi:10.1111/j.1600-6143.2010.03405.x.
Snyder LD, Medinas R, Chan C, Sparks S, Davis WA, Palmer SM, Weinhold KJ. Polyfunctional cytomegalovirus-specific immunity in lung transplant recipients receiving valganciclovir prophylaxis. Am J Transplant. 2011 Mar;11(3):553–560.
Journal cover image

Published In

Am J Transplant

DOI

EISSN

1600-6143

Publication Date

March 2011

Volume

11

Issue

3

Start / End Page

553 / 560

Location

United States

Related Subject Headings

  • Valganciclovir
  • T-Lymphocytes
  • Surgery
  • Risk Factors
  • Postoperative Complications
  • Pilot Projects
  • Middle Aged
  • Male
  • Lung Transplantation
  • Immunity, Cellular